[{"id":"b74e36f6-cf32-4921-b6ad-d7fa7621e27e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395533","created_at":"2022-05-27T11:56:28.484Z","updated_at":"2024-07-02T16:35:31.809Z","phase":"Phase 1","brief_title":"A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.","source_id_and_acronym":"NCT05395533","lead_sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TRS005"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-25"},{"id":"752ae712-ca59-4ac6-9980-5c5c51b9d5f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03057418","created_at":"2021-01-18T15:03:31.124Z","updated_at":"2024-07-02T16:37:21.837Z","phase":"Phase 1","brief_title":"Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim","source_id_and_acronym":"NCT03057418","lead_sponsor":"Biointegrator LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aurixim (rituximab conjugate)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-05-23"}]